Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Uncategorized

RF Lafferty Downgrades Brookfield Renewable to Hold, Lowers Price Target to $35

RF Lafferty analyst Jamie Perez downgrades Brookfield Renewable (NYSE:BEP) from Buy to Hold and lowers the price target from $49 to $35.

byBenzinga Newsdesk

May 4, 2021

1 minute read

RF Lafferty analyst Jamie Perez downgrades Brookfield Renewable (NYSE:BEP) from Buy to Hold and lowers the price target from $49 to $35.

Instagram Head Adam Mosseri to Temporarily Relocate to London

By Charles Gross

Today, 10:58 PM

- FT https://www.ft.com/content/5f240367-b199-425b-adc3-0526744e3677

Alibaba, Nio Stocks Rise: Hang Seng Reflects Caution Ahead Of FOMC Minutes Release

By Bhavik Nair

Today, 10:58 PM

Hong Kong stocks opened in the green on Wednesday, with the benchmark Hang Seng trading marginally higher ahead of the release of the FOMC minutes due later today.

BABA

JMP Securities Maintains Market Outperform on C3.ai, Lowers Price Target to $19

By Benzinga Newsdesk

Today, 10:58 PM

JMP Securities analyst Patrick Walravens maintains C3.ai (NYSE:AI) with a Market Outperform and lowers the price target from $25 to $19.

Teva Pharmaceutical Indus Q3 Adj. EPS $0.59 Misses $0.65 Estimate, Sales $3.89B Miss $4.03B Estimate; Reaffirms Guidance

By Benzinga Newsdesk

Today, 10:58 PM

Teva Pharmaceutical Indus (NYSE:TEVA) reported quarterly earnings of $0.59 per share which missed the analyst consensus estimate of $0.65 by 9.23 percent. This is a 1.72 percent increase over earnings of $0.58 per share

TEVA

RF Lafferty Downgrades Brookfield Renewable to Hold, Lowers Price Target to $35

Related Posts

Instagram Head Adam Mosseri to Temporarily Relocate to London

Alibaba, Nio Stocks Rise: Hang Seng Reflects Caution Ahead Of FOMC Minutes Release

JMP Securities Maintains Market Outperform on C3.ai, Lowers Price Target to $19

Teva Pharmaceutical Indus Q3 Adj. EPS $0.59 Misses $0.65 Estimate, Sales $3.89B Miss $4.03B Estimate; Reaffirms Guidance